Today: 20 May 2026
Browse Category

NASDAQ:IONS 22 August 2025 - 25 August 2025

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.
22 August 2025
·····

Stock Market Today

  • Celestica Inc: Over 20% Annualized Returns Anticipated Amid AI Hardware Surge
    May 19, 2026, 6:14 PM EDT. Celestica Inc (CLS) stands to gain from the growing demand for artificial intelligence (AI) hardware. This anticipated trend is expected to boost both the company's revenue (top-line) and profit margins, suggesting strong financial performance ahead. Analysts rate CLS stock as a Strong Buy, highlighting potential annualized returns exceeding 20%. Investors eyeing tech manufacturing and AI sectors may find Celestica's outlook particularly compelling amid evolving market dynamics.

Latest articles

JetBlue axes 12 routes; Fort Lauderdale responds

JetBlue axes 12 routes; Fort Lauderdale responds

20 May 2026
JetBlue will end all flights at Manchester-Boston Regional Airport on July 8 and cut nine other East Coast routes, shifting capacity to Fort Lauderdale. The move follows Spirit Airlines’ shutdown and increased competition in South Florida. JetBlue said Fort Lauderdale revenue per seat mile rose 5% in the first quarter. Manchester officials expressed disappointment, noting JetBlue made up no more than 5% of airport traffic.
Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

20 May 2026
The U.S. shipped a record 9.9 million barrels from its emergency oil reserve last week, cutting stocks to 374 million barrels. Brent crude settled at $111.28 a barrel Tuesday after signs of progress in U.S.-Iran talks, but Exxon and Chevron warned the market has not fully absorbed the impact of the Strait of Hormuz closure. The IEA reported global oil inventories fell by 246 million barrels in March and April.
Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

20 May 2026
Toll Brothers shares rose 2.7% to $127.50 in after-hours trading after quarterly profit and revenue topped Wall Street forecasts. Fiscal Q2 net income fell to $260.6 million from $352.4 million a year earlier, while home sales revenue dropped to $2.51 billion. The company raised its full-year delivery and pricing guidance despite high mortgage rates and softer industry sentiment.
Go toTop